Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The offering, which received shareholder approval on September 26, 2025, is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz. This financial move represents a strategic effort to bolster the company's working capital as it advances treatments for neurodegenerative, metabolic, and alcohol misuse disorders.
The completion of this private placement will significantly alter the company's voting structure, with voting rights attached to the Class A shares increasing to 75.27%. This restoration brings the voting rights nearly back to their original level when Quantum BioPharma went public in 2018, representing a substantial consolidation of control by the participating entities. The transaction underscores the confidence of key stakeholders in the company's direction and future prospects within the competitive biopharmaceutical landscape.
Quantum BioPharma's research and development efforts focus on challenging medical conditions through its wholly owned subsidiary, Lucid Psycheceuticals Inc. The company's lead compound, Lucid-MS, represents a significant advancement in multiple sclerosis treatment, having demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the fundamental mechanism underlying multiple sclerosis, making this development particularly important for patients suffering from this debilitating neurological condition.
Beyond its pharmaceutical developments, Quantum BioPharma maintains strategic business interests through its ownership stake in Unbuzzd Wellness Inc., where it retains 20.11% ownership as of March 31, 2025. The agreement includes royalty payments of 7% of sales from the unbuzzd(TM) product until payments to Quantum BioPharma total $250 million, after which the royalty decreases to 3% in perpetuity. The company preserves full rights to develop similar products for pharmaceutical and medical applications, maintaining flexibility for future medical innovations.
The company's financial strategy extends beyond direct pharmaceutical development through its wholly owned subsidiary, FSD Strategic Investments Inc., which manages a portfolio of strategic investments representing loans secured by residential or commercial property. This diversified approach to resource management provides additional financial stability as the company navigates the capital-intensive process of drug development and clinical trials. Investors can access the latest news and updates relating to QNTM through the company's newsroom at https://ibn.fm/QNTM.
This private placement announcement comes at a critical time for biopharmaceutical companies facing increasing research costs and regulatory hurdles. The funding will support Quantum BioPharma's continued development of treatments for conditions that affect millions worldwide, including neurodegenerative disorders like multiple sclerosis and metabolic conditions that represent growing global health concerns. The successful completion of this offering could signal strengthened investor confidence in the company's pipeline and strategic direction.
